Suchergebnisse
10
Alles
Such-Filter
Tag
obesity
Obesity Market Analysis and Sales Forecasts, 2021-2024 & 2025-2031
27. März 2025 12:16 ET
|
Research and Markets
Dublin, March 27, 2025 (GLOBE NEWSWIRE) -- The "Obesity: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering. Across the 68 markets, sales in the...
NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market
27. März 2025 08:00 ET
|
PMGC Holdings Inc.
NorthStrive Biosciences Inc. Signs Amended Licensing Agreement with Existing Licensor, Aims to Capture Animal Health Market
Helicore Biopharma Announces First Participant Dosed in Phase 1 Clinical Trial of HCR-188, a First-in-Class GIP Antagonist for the Treatment of Obesity
25. März 2025 09:00 ET
|
Helicore Biopharma
Helicore Biopharma Announces First Participant Dosed in Phase 1 Clinical Trial of HCR-188, a First-in-Class GIP Antagonist for the Treatment of Obesity
Ampersand Biomedicines Raises Series B Financing and Highlights Pipeline Advancements
19. März 2025 07:00 ET
|
Ampersand Biomedicines
$65 million in Series B funding secured from investors, including founder Flagship Pioneering and Eli Lilly & Company Two lead programs in immuno-inflammation and immuno-oncology planned to enter...
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
17. März 2025 03:00 ET
|
Zealand Pharma
Press release – No. 4 / 2025 Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity Initiated in December 2024, the...
Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with overweight and obesity
12. März 2025 02:00 ET
|
Zealand Pharma
Company announcement – No. 4 / 2025 Zealand Pharma and Roche enter collaboration and license agreement to co-develop and co-commercialize petrelintide as a future foundational therapy for people with...
Northstrive Biosciences Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1
10. März 2025 08:00 ET
|
PMGC Holdings Inc.
Northstrive Biosciences, Inc. Schedules Pre-IND Meeting with FDA for EL-22, an Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination
ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes
05. März 2025 07:52 ET
|
ZyVersa Therapeutics
Inflammasome inhibition in obese animal model with heart failure was cardioprotective & improved metabolic parameters.
Alberta Declares March 4 as World Obesity Day, Recognizing Obesity as a Chronic Disease
04. März 2025 00:01 ET
|
Obesity Canada
Alberta has become the first province in Canada to officially recognize obesity as a chronic disease.
Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight
21. Februar 2025 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Evolving Landscape of Obesity: Key Market Insights of Latest Published Different Types of Obesity | DelveInsight The obesity market size is...